Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology. 2015;61(5):1471-1478.

Publication Type:

Journal Article

Authors:

Z M Younossi; Jiang, Y.; Smith, N.J.; Stepanova, M.; Beckerman, R.

Source:

Hepatology, Volume 61, Issue 5, p.1471-1478 (2015)

Keywords:

Absenteeism, analogs & derivatives, Antiviral Agents, Benzimidazoles, clinical trial, Clinical Trials, Cost Savings, Costs and Cost Analysis, Disease, drug therapy, economics, Efficiency, eradication, Evaluation Studies, Fluorenes, Genotype, genotype 1, HCV, Health, hepatitis, Hepatitis C, Hepatitis C,Chronic, Humans, Infection, interferon, Liver, Liver Diseases, Medicine, Models,Economic, Patients, pegylated, pegylated interferon, Research, Research Support, Ribavirin, sofosbuvir, SVR, therapeutic use, Time, treatment, United States, Uridine, Uridine Monophosphate, Washington, Work

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25706754

Export Citation:

RIS Format

Top